Best for
Mobile
How to buy Illumina shares
Own Illumina shares in just a few minutes. Share price changes are updated daily.
Fact checked
Illumina, Inc (ILMN) is a leading diagnostics & research business based in the US. Illumina is listed on the NASDAQ and employs 7,700 staff. All prices are listed in US Dollars.
How to buy shares in Illumina
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: ILMN in this case.
- Research Illumina shares. The platform should provide the latest information available.
- Buy your Illumina shares. It's that simple.
What's in this guide?
- Can I buy shares in Illumina?
- Illumina shares summary
- Compare share dealing platforms
- Is Illumina stock a buy or sell?
- Can I short Illumina shares?
- Is Illumina suitable for ethical investing?
- Are Illumina shares over-valued?
- Illumina's financials
- How volatile are Illumina shares?
- Does Illumina pay a dividend?
- Have Illumina shares ever split?
- Other common questions
Illumina share price
Use our graph to track the performance of ILMN stocks over time.Illumina shares at a glance
Information last updated 2021-01-23.
| 52-week range | $196.78 - $408.81 |
|---|---|
| 50-day moving average | $366.7794 |
| 200-day moving average | $344.2495 |
| Wall St. target price | $324.81 |
| PE ratio | 94.1701 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $4.314 |
Invest in Illumina shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Illumina stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Illumina under- or over-valued?
Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Illumina's P/E ratio
Illumina's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 94x. In other words, Illumina shares trade at around 94x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Illumina's PEG ratio
Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4114. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Illumina's EBITDA
Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $1 billion.
The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.
Illumina financials
| Revenue TTM | $3.2 billion |
|---|---|
| Operating margin TTM | 25.48% |
| Gross profit TTM | $2.5 billion |
| Return on assets TTM | 7.12% |
| Return on equity TTM | 13.96% |
| Profit margin | 19.7% |
| Book value | $32.192 |
| Market capitalisation | $59.3 billion |
TTM: trailing 12 months
How to short and sell Illumina shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "ILMN.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 5.0 million Illumina shares held short by investors – that's known as Illumina's "short interest". This figure is 4.6% down from 5.2 million last month.
There are a few different ways that this level of interest in shorting Illumina shares can be evaluated.
Illumina's "short interest ratio" (SIR)
Illumina's "short interest ratio" (SIR) is the quantity of Illumina shares currently shorted divided by the average quantity of Illumina shares traded daily (recently around 1.1 million). Illumina's SIR currently stands at 4.7. In other words for every 100,000 Illumina shares traded daily on the market, roughly 4700 shares are currently held short.
However Illumina's short interest can also be evaluated against the total number of Illumina shares, or, against the total number of tradable Illumina shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Illumina's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Illumina shares in existence, roughly 30 shares are currently held short) or 0.039% of the tradable shares (for every 100,000 tradable Illumina shares, roughly 39 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Illumina.
Find out more about how you can short Illumina stock.
Illumina's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Illumina.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Illumina's total ESG risk score
Total ESG risk: 9.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Illumina's overall score of 9.18 (as at 01/01/2019) is excellent – landing it in it in the 2nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Illumina is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Illumina's environmental score
Environmental score: 2.22/100
Illumina's environmental score of 2.22 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Illumina's social score
Social score: 2.6/100
Illumina's social score of 2.6 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Illumina's governance score
Governance score: 5.36/100
Illumina's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Illumina is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Illumina's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Illumina scored a 1 out of 5 for controversy – the highest score possible, reflecting that Illumina has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Illumina, Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 9.18 |
|---|---|
| Total ESG percentile | 2.42 |
| Environmental score | 2.22 |
| Environmental score percentile | 2 |
| Social score | 2.6 |
| Social score percentile | 2 |
| Governance score | 5.36 |
| Governance score percentile | 2 |
| Level of controversy | 1 |
Illumina share dividends
We're not expecting Illumina to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have Illumina's shares ever split?
Illumina's shares were split on a 2:1 basis on 23 September 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.
Illumina share price volatility
Over the last 12 months, Illumina's shares have ranged in value from as little as $196.78 up to $408.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 1.1334. This would suggest that Illumina's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Illumina overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.
Frequently asked questions
More guides on Finder
-
How to buy Transportation and Logistics Systems shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy CloudCommerce shares
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert